Methylphenidate and dexmethylphenidate formulations in children with attention-deficit/hyperactivity disorder by Sugrue, David
University of Connecticut
OpenCommons@UConn
Honors Scholar Theses Honors Scholar Program
Spring 5-1-2015
Methylphenidate and dexmethylphenidate
formulations in children with attention-deficit/
hyperactivity disorder
David Sugrue
University of Connecticut School of Pharmacy, david.sugrue@uconn.edu
Follow this and additional works at: https://opencommons.uconn.edu/srhonors_theses
Part of the Pharmacy and Pharmaceutical Sciences Commons
Recommended Citation
Sugrue, David, "Methylphenidate and dexmethylphenidate formulations in children with attention-deficit/hyperactivity disorder"
(2015). Honors Scholar Theses. 435.
https://opencommons.uconn.edu/srhonors_theses/435
David Sugrue | 1  
 
Abstract: 
Purpose: To review the current literature on the various extended-release methylphenidate 
stimulant preparations regarding safety and efficacy in children and adolescents with attention-
deficit/hyperactivity disorder (ADHD). 
 
Summary: The literature reviewed establishes the efficacy of the different long-acting 
methylphenidate stimulant formulations in treating children and adolescents with ADHD. 
Comparing and contrasting the different extended-release preparations allows for clinicians to 
help tailor ADHD treatments to individual patients. The extended release methylphenidate 
products provide the same efficacy as the immediate release formulations, but add the 
convenience of less frequent dosing. There are a few options for patients with difficulty 
swallowing tablets or capsules, including the Daytrana® transdermal patch and the liquid 
Quillivant XR®. Focalin XR®, Metadate CD®, and Ritalin LA® can all be opened and sprinkled 
on applesauce.  
 
Conclusions: Extended-release methylphenidate is effective in treating the symptoms of ADHD 
in children and adolescents. The different available dosage forms gives the clinician the 
opportunity to individualize treatment based on patient needs.  
 
* Data Sources: The literature included was retrieved from PubMed/MEDLINE using the terms 
methylphenidate, stimulant, extended-release, children, and attention/hyperactivity disorder. 
Reference citations from publications identified were also reviewed. 
 
Study Selection and Data Extraction: Double-blind clinical trials found using the search strategy 
above were included in this review. Open-label studies were included if no double-blind trials 
were published for that methylphenidate preparation. 
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Introduction 
 Attention-deficit hyperactivity disorder (ADHD) affects approximately 5% of school 
aged children worldwide. The disease typically presents in early child hood and can significantly 
impair academic achievement and development.1 Children with ADHD may present with 
symptoms including hyperactivity, impulsivity, and inattention which are all more pronounced 
than expected for a child’s developmental age.2 These symptoms can persistent all the way into 
adolescence and adulthood, impairing the child’s development in all stages. The etiology of 
ADHD is still not known, but evidence has shown that it consists of neurologic components and 
the child’s environmental factors.3  
ADHD can be treated with medications, behavioral therapy, or a combination of the two. 
Stimulants including methylphenidate and amphetamine are considered first line drug treatment.4 
There are many approved formulations of methylphenidate available on the market, therefore 
prescribers need to make clinical decisions as to which formulation is appropriate to initiate 
therapy or change therapy if needed. Prescribers, such as physicians and nurse practitioners, have 
the ability to tailor pharmacological therapy to meet the needs of each individual patient The 
objective of this paper is to review and compare the current methylphenidate preparations 
available for children to provide clinicians with the opportunity to individualize their patients’ 
therapy. By summarizing the information and data from current literature on the topic in this 
article, prescribers have access to the data needed to optimize ADHD therapy.   
  
Methods  
 Working in a community pharmacy setting, I have interacted with patients and caregivers 
to ensure that their methylphenidate prescriptions are filled appropriately and safely. This 
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process often includes counseling the parent on the medication, communicating with the 
prescriber, and managing the logistics of providing the medication for the patient. There are 
many factors that affect the prescription when being filled at the pharmacy including patient-
specific factors, insurance billing and cost, and availability of the drug product. All of these 
factors have the potential to inhibit the ability for the patient to receive the medication: child is 
experiencing adverse effects from medication, mediation is too expensive or is not covered by 
insurance plan, product is not currently available on the market, and other problems that may 
arise. As the pharmacist, it is our responsibility to contact the prescriber in these circumstances 
and discuss alternatives appropriate for the patient.  
 Since there are many available formulations to choose from, I wanted to create a 
document to utilize during these situations that would enable the prescriber to choose an agent to 
treat the symptoms experienced by the patient. In order to accomplish this I performed a 
literature search via PubMed/MEDLINE using the terms methylphenidate, stimulant, extended-
release, children, and attention/hyperactivity disorder. In addition, reference citations from 
publications found were reviewed. Double-blind clinical trials found using the search strategy 
above were included in this review. Open-label studies were included if no double-blind trials 
were published for that methylphenidate preparation. I chose to limit my search to 
methylphenidate because it has become the more commonly prescribed initial medication for 
children with ADHD.5 
Results 
 The data I obtained from the search is presented below and was constructed into an 
article that was published in the American Journal of Health-System Pharmacy (Am J Health-
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Syst Pharm. 2014; 71:1163-70). Included in the article is Table 1, which provides summary data 
on currently available methylphenidate and dexmethylphenidate products.  
Background 
 The main pharmacological treatment choice for ADHD has been stimulant medications. 
Over the last 35 years, methylphenidate has replaced amphetamine as the primary stimulant 
prescribed to treat ADHD.5 The Food and Drug Administration (FDA) approved the use of 
methylphenidate for the treatment of ADHD in 1955. All formulations excluding the 
methylphenidate patch are approved for the use in children over the age of 6.6 The mechanism of 
action of methylphenidate is its proposed ability to increase dopamine concentrations within the 
synapse. Methylphenidate blocks the dopamine transporters therefore reducing uptake of the 
neurotransmitter.7 Through Positron Emission Tomography (PET) it was determined that 
therapeutic doses of methylphenidate block over 50% of the dopamine transporters with d-threo-
methylphenidate as the isomer that blocks the transporters.8  
 The mechanism of methylphenidate differs from the amphetamines in selectivity due to 
its main actions through the dopaminergic pathway, and to a lesser extent through 
norepinephrine. Amphetamines in contrast increase the release of both dopamine and 
norepinephrine as well as increasing extracellular serotonin.9 Methylphenidate has consistently 
shown efficacy and safety in comparison to placebo in the management of inattention, 
impulsivity, and hyperactivity symptoms in children.10 
 The adverse effects of the various methylphenidate formulations are similar across the 
group of medications. The side effects are dose-dependent, mild in severity, and can diminish 
with a change in medication dose or timing.11 The most common adverse effects reported by 
children receiving stimulants are loss of appetite, insomnia, headaches, and stomachaches. These 
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side effects may subside after the first two weeks of treatment, but adverse effects are the main 
reason stimulant treatment is discontinued.12 Proper drug administration may abate some of these 
adverse effects. For example patients on extended-release methylphenidate preparations should 
eat large meals in the morning and evening, when methylphenidate levels are the lowest to 
prevent anorexia.13 Doses too late in the day should be avoided due to methylphenidate’s 
stimulant effects that may prompt insomnia.  
 A major concern with methylphenidate is its short half-life of 2.5 hours in children, 
creating a difficult dosing schedule. The elimination half-life is reported to be within the range of 
2 to 6 hours, but most studies report an average of 2 to 3 hours.13 Children with ADHD require 
pharmacotherapy in order to reduce symptoms, to help promote better learning abilities while at 
school as well as in after school programs and at home. Short acting drugs will not cover the full 
school day requiring a school official or nurse to administer a second dose. Providing the child 
with an extended release methylphenidate formulation can reduce the dose frequency and 
potentially reduce incidence of side effects. 
Intermediate-release oral methylphenidate 
 In order to decrease the frequency of methylphenidate doses, reduce the incidence of side 
effects, and increase efficacy, sustained release formulations were developed. Sustained release 
formulations also reduce abuse potential liability and severity of adverse effects such as 
tachycardia.13 Ritalin SR ®, Methylin ER®, and Metadate ER® are all AB rated by the FDA even 
though they employ different matrices.6 Ritalin SR® and Metadate ER® deliver methylphenidate 
to the patient via a wax matrix for an approximated duration of action of 8 hours.15 Average time 
to peak concentrations (Tmax) for these products is 4.7 hours (1.3-8.2).15,16  The 
methylphenidate in the intermediate release products is more slowly but as extensively absorbed 
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as the immediate release tablets.17 Drug release through a matrix layer occurs in 2 stages: the 
first stage is the formation of a water channel, then the second stage is the release of drug 
through the channel. The release rate is a function of the permeability coefficient and thickness 
of the matrix layer.18 Due to the matrix technology, these formulations should be swallowed 
whole, not crushed or chewed. Splitting the tablets would increase the total surface area, 
therefore increasing drug release too early. Crushing or chewing the tablets destroys the wax 
matrix, which also reduces the sustained release properties. Taking the dose of the sustained 
release products with food results in a greater Cmax and AUC, so it is recommended to take each 
dose 30 to 45 minutes before a meal.15,16 
 Methylin ER® uses a dual acting hydrophilic polymer release technology, which controls 
the release of methylphenidate by diffusion and erosion. This technology allows drug to diffuse 
out of the hydrophilic gel, leading to tablet disintegration. This product should also be swallowed 
whole, 30 to 45 minutes before a meal, with water or another liquid. Methylin ER® can have 
effects that last up to 8 hours.17  
Since these intermediate agents last up to 8 hours, they can be dosed once daily, but most 
patients will still require twice daily dosing to provide symptom control throughout the school 
day and after school at home.14 The sustained release plasma profile demonstrates that it takes 
almost 5 hours for peak concentrations so, patients may not experience full symptom control 
until mid-afternoon. For school aged children, this formulation may prove less useful if they are 
still experiencing ADHD symptoms in the beginning of their school day. 
Long-acting oral methylphenidate 
Concerta 
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 Methylphenidate is also available in an extended-release tablet Concerta®. Concerta® 
employs OROSTM (osmotic controlled released oral delivery system) technology to deliver 
methylphenidate at a controlled rate.19 Each tablet is created to allow a once daily oral 
administration that has a 12 hour duration of effect. The Concerta® tablets are comprised of an 
osmotically active trilayer core that is surrounded by a semipermeable membrane with an 
immediate release coating. The trilayer core contains a push layer of osmotically active 
components and two drug layers containing drug and excipients. When the tablet is taken orally, 
the drug overcoat dissolves within one hour in an aqueous such as the gastrointestinal tract 
providing an immediate release of methylphenidate.  The tablet has a precision-laser drilled 
orifice on the drug layer end. After the overcoat dissolves, water is able to permeate through the 
membrane into the tablet core and as the osmotically active polymer push layer expands, 
methylphenidate is released through the tablet’s drilled orifice. The semipermeable membrane of 
Concerta® is what controls the rate at which water enters the tablet, therefore it is also controlling 
drug release from the tablet. Drug release rate increases with time over a period of 6 to 7 hours 
due to the concentration gradient of drug incorporated into the drug layers within the trilayer 
core. The rigid coating remains intact and is eliminated in the stool as a tablet shell.19 
 Children six to twelve years of age should not exceed 2mg/kg/day or 54mg of Concerta®, 
according to the package insert. Adolescents and adults can be titrated up to the 72mg tablet if 
needed for symptom control. The plasma profile of Concerta® is similar to the profile of 
immediate release methylphenidate dose three times a day.19 A study compared the effects of 
Concerta® to immediate-release methylphenidate given 2 or 3 times a day and placebo; outcomes 
in the study were measured using the Swanson, Nolan and Pelham-Fourth Edition rating scale 
consisting of 18 ADHD symptoms. The study resulted in statistically significant superiority of 
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Concerta® to immediate release methylphenidate in remission rate of ADHD symptoms and 
severity of ADHD symptoms (-19.6±13.9 vs -14.3±11.6, p=0.01).20 This study also used a Parent 
Stress Index as an outcome which revealed that parents with children on Concerta® had a 
significantly greater decrease in parental stress than the parents in the IR methylphenidate group 
(14.0±19.2 vs. 6.1±14.8, p=0.008).20 
 There are no differences in the pharmacokinetics of Concerta® when administered after a 
high fat breakfast, so the dose can be taken with or without food. Concerta® tablets should not be 
crushed or chewed, but swallowed whole with liquids. Plasma concentrations of Concerta® reach 
an initial maximum at about 1 hour and then gradually increase over the next 5 to 9 hours. 
Concerta® minimizes the fluctuations between peak and trough concentrations associated with 
the immediate release tablets taken three times a day.19 
 Another study compared the efficacy of Concerta to three times daily immediate release 
methylphenidate in children diagnosed with ADHD, 6 to 12 years old. 21 Results were reported 
using a parent and teacher recorded Daily Report Card which incorporated specific goals based 
on areas requiring improvement for each patient. There was an overall effect of drug, both 
immediate release and Concerta®, for all the criteria of the Daily Report Card compared to 
placebo (p<0.01). Concerta® and the three times dosing IR methylphenidate had similar efficacy 
in most measures, with Concerta® having superiority in two of the parent ratings (p<0.05) 
establishing Concerta®’s ability to provide symptom control throughout a 12 hour period. With 
one morning dose, the effects of Concerta provided coverage through school, afternoon, and 
evening behavior.21 When deciding between the once daily methylphenidate formulations, it is 
important to consider when throughout the day the patient needs the most symptom control.  
Ritalin LA  
David Sugrue | 9  
 
Ritalin LA® capsules, different from the Ritalin SR® tablets, have a bi-modal release 
profile which provides an immediate release as well as an extended-release component.22 The 
bead filled capsules utilize so called SODAS® (spheroidal oral drug adsorption system) 
technology, which coats an inert sugar sphere that contains the active product ingredient with 
either an immediate or controlled release coating. This mixture allows the full dose to provide a 
pulsatile drug release profile. Ritalin LA® capsules are bead filled with the capsule containing a 
50:50 mixture of immediate release beads and enteric coated delayed-release beads, thereby 
providing the bi-modal profile.22 
 Ritalin LA® provides in a single dose, the same amount of methylphenidate immediate 
release dosages given twice daily respectively. The plasma profile of Ritalin LA® reveals the two 
distinct peaks, with the time to first peak being 1 to 3 hours and the second peak achieved around 
6 hours (5-11). The Ritalin LA® capsules have less peak and trough fluctuations than the 
immediate release methylphenidate tablets and have higher interpeak minimum concentrations.22 
The release mechanism allows for the same total dose of methylphenidate to be provided for a 
longer, constant duration.  
 The advantage of Ritalin LA® capsules is that the dose can be sprinkled on top of 
applesauce if the patient has difficulty swallowing the capsule whole.22 Per the package insert, if 
the patient chooses to sprinkle the dose over a spoonful of applesauce, the applesauce should not 
be warm and the mixture of drug and applesauce should be consumed immediately and entirely. 
The drug and applesauce mixture should not be stored for a future dose because it could disturb 
the release properties. If the applesauce and drug mixture is stored, the drug coating will 
potentially hydrate prematurely. The modified release properties of Ritalin LA® are pH 
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dependent, so coadministration of antacids or acid suppressants should be avoided as it could 
alter the release of methylphenidate.22 
 Another advantage of Ritalin LA® capsules is that its absorption is independent of food 
intake. The morning dose can be taken with or without breakfast and still maintain the same first 
peak concentration and extent of absorption.23 Ritalin LA® capsules have also been compared to 
Concerta® in a single-blind, placebo-controlled, crossover study.24 In the study, Ritalin LA® 
reached its first peak quicker, with a Ritalin LA® 20mg capsule being statistically more 
efficacious with a greater mean change from predose Swanson, Kotkin, Atkins, M-Flynn, and 
Pelhma (SKAMP)scores 4 hours post-dose than a Concerta® 36mg tablet (34.1 vs. 24.6, 
p=0.043). Although not statistically significant, Concerta® provided greater late day symptom 
control 8 to 12 hours post dose than Ritalin LA® (33.8 vs. 20.9, p=0.208).24 The differences in 
time to effect and duration of stimulant effect of the methylphenidate products should be 
considered when individualizing therapy.  
Metadate CD  
 Methylphenidate CD (Metadate CD®), different from the product Metadate ER®, is a 
bead filled capsule containing a mixture of 30% immediate release beads with 70% extended 
release beads (i.e. a 40mg Metadate CD® capsule is composed of 12mg bead and 28mg extended 
release beads).25 A study compared methylphenidate CD capsules of 30:70 and 40:60 
formulations to determine which had better symptom control throughout based on two different 
dosage strategies over the course of a child’s school day. Both formulations showed a significant 
reduction in SKAMP-A scores compared to placebo, but only the 30:70 formulation was still 
superior over placebo 9 hours post dose.26 
David Sugrue | 11  
 
 The release rate of methylphenidate from the Metadate CD® capsules is fairly smooth 
much like Ritalin LA®, with less peak and trough fluctuations than 2 methylphenidate immediate 
release tablets taken 4 hours apart. 25 The first peak concentration from the Metadate CD® 
capsules was observed approximately 1.5 hours after dose intake and the second peak was 
reached about 4.5 hours after dose administration. In a study comparing food effects on plasma 
concentration, a high fat meal delayed the first peak concentration by approximately 1 hour, so 
the dose should be taken in the morning before breakfast. According to the package insert, the 
contents of Metadate CD® capsules can be sprinkled over a tablespoon of applesauce and 
consumed right away without affecting bioavailability. The sprinkled dose should be taken 
immediately and entirely.25 
 A multi-center, double blind cross over study compared the effects of Metadate CD® and 
comparable doses of Concerta® to placebo. Both Metadate CD® and Concerta® showed superior 
efficacy in the reductions of SKAMP scores compared to placebo (p<0.001) but there were 
differences in effect throughout the time of day. Based on SKAMP measures, Metadate CD® 
40mg had greater symptom control than Concerta® 18mg from dose administration to six hours 
post dose (14.17 vs. 17.00, p<0.001). There was no significant difference between the two 
formulations at 7.5 hours and 12 hours post administration. A higher dose of Concerta® 54mg 
provides significant reductions in symptoms at 12 hours than high dose 60mg Metadate CD® 
(16.74 vs. 19.85, p<0.05). For a child that requires more symptom control throughout an average 
length of a school day of around seven hours Metadate CD® would be more appropriate than 
Concerta®. Concerta® provides better late day symptom control than Metadate CD® and 
placebo.27 
Transdermal methylphenidate 
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 Methylphenidate is also available as a transdermal patch (Daytrana®) that has FDA 
approval for children of the ages 6 to 12 years. The Daytrana® patch is commercially available as 
12.5cm2, 18.75cm2, 25cm2, and 37.5cm2 sized patches with respective 10, 15, 20, and 30mg 
doses that represent the total amount of methylphenidate delivered over 9 hours.28 Transdermal 
methylphenidate is not eliminated in the liver by first-pass metabolism, while oral 
methylphenidate is, therefore the dosage forms are not bioequivalent. When beginning the 
Daytrana® patch it is recommended to start at the 10mg dose, whether the patient is just starting 
methylphenidate or converting from another dosage form.28 Transdermal delivery of 
methylphenidate provides a treatment option for children who have difficulty swallowing oral 
medications or if they would benefit from tailoring the duration of effect specifically for their 
daily needs.29 
 The Daytrana® patch is a multipolymeric adhesive platform that is designed to release 
methylphenidate consistently upon application to intact skin. The methylphenidate is dispersed in 
an acrylic adhesive that is then dispersed into a silicone adhesive. The patch consists of three 
layers: a polyester/ethylene vinyl acetate laminate film backing that faces the outer surface, the 
adhesive layer containing methylphenidate, and a fluoropolymer-coated protective liner that 
must be removed before patch application.29 The Daytrana® utilizes DOT Matrix technology 
where the active ingredient is solubilized in high concentrations in an acrylic adhesive. The drug 
acrylic adhesive is then mixed with a silicone adhesive allowing for concentrated drug cells in an 
uncompromised silicone adhesive. DOT Matrix technology allows for better adhesion to 
application site and more drug concentrated a through smaller area. 
 The advantage of the patch is that it can be removed at any time, therefore the duration of 
methylphenidate exposure can allow for individualized treatment schedules. Effect from the 
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methylphenidate patch was seen 2 hours post application and up to 3 hours after removal in 
clinical trials.30,31 This 3 hour post-removal duration of effect should be considered in 
determining when to remove the patch each day. Parents should apply the patch to children to 
insure proper application and adherence. The Daytrana® patch has a side effect profile that is 
similar to the other methylphenidate formulations. The patch may cause skin irritation at the site 
of application that would present with erythema and papules. Redness and papules will disappear 
within 24 to 36 hours of patch removal.30 Disadvantages to the patch are that effects are not seen 
until 2 hours after application, meaning parents might have to apply patch to children while they 
are still sleeping in the morning.31 
Proper education for patch wearers and parents is necessary in order to promote appropriate 
absorption and drug delivery. Children need to be informed not to remove the patch until 
instructed to do so to maintain proper drug delivery. While the patches can be worn while 
swimming or exercising, if the patch does fall off and will not adhere back on to skin, the patient 
may apply a new patch on. The total wear time between both patches should not exceed more 
than 9 hours per day. Daytrana® patches should be applied to the hip, beneath underwear, at 
rotating sites as described in the product insert.28 Applying the patch to the hip minimizes skin 
absorption differences.32 The application site should be clean, dry, and be void of any cuts or 
previous irritation. Once the patch is applied, the patient should not apply any heat to the area 
(blow dryers, direct sunlight, electric blankets) because heat can increase the rate and amount of 
drug release from the transdermal delivery system. The patch should not be cut, and if the patch 
is cut or damaged it should no longer be used.28 
Methylphenidate extended-release oral liquid 
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 Until recently there were no extended release methylphenidate products available as oral 
suspensions for children with difficulty swallowing tablets or capsules. Quillivant XR® is a new 
product available to treat ADHD, being the first methylphenidate powder that is reconstituted 
with water creating an extended release liquid formulation. This new product is intended to be 
prescribed as once daily oral administration. The powder is composed of cationic matrix 
polymers that can bind to the racemic d-l-methylphenidate mixture by ion exchange. The 
Quillivant XR® powder contains 20% immediate release and 80% extended release 
methylphenidate components.33 The combination of multiple release profiles is possible due to 
the differences in the coating of the powder particles. A coating of varying thickness is applied to 
the intended extended release particles, creating an overall blend of coated and uncoated 
particles.35  
The reconstituted liquid is available as a 25mg per 5mL oral suspension that does not 
require refrigeration.33 Quillivant XR® is stable for up to 4 months after reconstitution when 
stored at room temperature (15-30°C). Prior to each dose, parents should shake Quillivant XR® 
suspension well for at least 10 seconds to ensure that a proper dose is administered.33 In an open-
label, single-dose study in children with ADHD ages 6 to 17 years, the average time to peak 
concentration was between 2 to 4 hours post dose.35 A double-blind, placebo-controlled, 
laboratory classroom study evaluated the efficacy of Quillivant XR® in children ages 6 to 12 
years. Quillivant XR® had significantly lower SKAMP scores from placebo at each time point 
tested to the last time tested at 12 hours post-dose (p<0.002). The onset of action of Quillivant 
XR® was demonstrated at 45 minutes in the study, the first time point measured.34 
While Quillivant XR® has been shown efficacious for a duration of 12 hours in studies against 
placebo, future trials need to be conducted comparing it to other available extended-release 
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methylphenidate formulations.34 Since Quillivant XR® is an oral suspension, it could become the 
preferred methylphenidate product in children with ADHD with difficulty swallowing. 
Dexmethylphenidate 
 The methylphenidate compound exists as four isomer structures including the d-threo, l-
threo, d-erythro, and l-erythro. The erythro isomers are not used in current methylphenidate 
stimulant products because the stimulant activity actually resides in the threo racemate.36 The 
methylphenidate products discussed earlier are racemic mixtures of 50% d-threo and 50% l-threo 
isomers of methylphenidate. Preclinical studies have demonstrated that the d-threo isomer (d-
MPH) is pharmacologically more active than the l-threo isomer.37 One clinical study of children 
with ADHD found that d-MPH was just as effective as the d,l-MPH mixture 2 hours after 
administration, and no effect was seen for the l-threo isomer.36 Since the d-threo isomer can be 
isolated and proven to be efficacious, the dose of dexmethylphenidate (d-MPH) can be half of 
the methylphenidate dose.38 
 A randomized, double-blind, intent-to-treat study of children ages 6 to 17 years was 
conducted to demonstrate the efficacy of dexmethylphenidate compared to d-l-methylphenidate, 
with the dexmethylphenidate being administered at half the dose of methylphenidate.39 
Participants were initiated on either 2.5mg of dexmethylphenidate twice daily or 5mg of d-l-
methylphenidate twice daily, and titrated up to a maximum of 10mg of dexmethylphenidate 
twice a day and 20mg of racemic methylphenidate twice a day. Outcomes were reported using 
the teacher-completed Swanson, Nolan, and Pelham Rating Scale (Teacher SNAP). Doses were 
administered by parents between 7:00 and 8:00am. Dexmethylphenidate provided significant 
decreases from baseline in the SNAP in the early afternoon assessment at 3:00pm (-0.7, 
p<0.0001) and in the late evening assessment at 6:00pm (-0.6,p=0.0003). While the racemic d-l-
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methylphenidate provided early afternoon symptom control (-0.6,p=0.0073) it did not provide 
significant control at the late day assessment time. The d-threo methylphenidate group, racemic 
mixture group, and placebo all had comparable side effect reporting and frequency.39 An 
extended release formulation of dexmethylphenidate was introduced, Focalin XR® to eliminate 
the midday dose of dexmethylphenidate immediate release, reduce side effects, and provide 
smoother plasma concentrations.40 
Extended-release dexmethylphenidate 
 Focalin XR® is another extended release formulation that utilizes the proprietary 
SODAS® technology to provide an immediate release and a second release of drug about 4 hours 
later. The initial rate of absorption of Focalin XR® is similar to that of its immediate release 
formulation with a time to first peak around 1.5 hours.40 The second peak is reached about 4 
hours later with a range of 4.5 to 7 hours after administration. Focalin XR® exhibits less peak 
and trough fluctuations than the immediate release tablets given in 2 doses 4 hours apart.40 No 
racemization occurs with dexmethylphenidate extended release after administration and similar 
efficacy is achieved at half the dose of d,l-methylphenidate extended release.39 
 The SODAS® extended release technology is pH dependent, so antacids should not be 
administered with Focalin XR as it may alter drug release. Focalin XR® may be taken with or 
without food, but absorption of the d,l-methylphenidate may be slowed down by the 
consumption of a high fat breakfast and it is expected to have the same effect on 
dexmethylphenidate.40 The Focalin XR® capsules may be opened as stated in the package insert 
and sprinkled over a spoonful of applesauce and consumed right away if the child has a difficult 
time swallowing whole capsules.40 
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 A randomized, multicenter, double-blind, crossover study compared the effects of 
Focalin XR® to Concerta® tablets in children with ADHD aged 6 to 12 years. In the study, 
Focalin XR® had a faster onset of action than Concerta®, with significantly greater mean change 
in SKAMP score 2 hours post dose (10.65 vs. 5.94, p<0.001). Effects of Focalin XR® and 
Concerta® could be seen as early as 0.5 hours post dose in comparison to placebo, but Focalin 
XR® demonstrated stronger symptom ADHD control with a greater difference in SKAMP scores 
(p=0.044).41 The study outcomes favored Focalin XR® at each time point from 1 to 6 hours post 
dose (p<0.05). It wasn’t till 10 hours post dose that Concerta® retained greater improvements in 
the study outcomes. During the last few hours of the laboratory classroom day, Concerta® 
provided better effects than Focalin XR® (p<0.05 at 10 hours, p<0.001 at 11 and 12 hours).41 
This information could be useful in choosing the correct medication depending on when 
symptom control is needed the most throughout the patient’s day. 
Conclusion 
 The availability of the different extended-release formulations of methylphenidate can be 
used as options in treatment to satisfy individual needs.  The methylphenidate products are all 
equally efficacious in treating ADHD symptoms. Clinicians can utilize the advantages and 
disadvantages of each product in order to individualize their patient’s treatment. 
Methylphenidate regimens can then provide patients with the ability to focus as suits them in 
their daily routine.  
 There are many other factors when deciding on appropriate therapy for a patient, aside 
from just the pharmacokinetics and pharmacodynamics of the medication. Until recently many of 
the extended-release formulations were accessible on the market as the brand name agent, with 
no generics available for a cheaper substitution. Another determinant is whether the desired 
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medication is on the patient’s insurance formulary, the list of drugs that are preferred by their 
health care plan. These factors, like cost and market availability, need to be taken into 
consideration as they can be barriers to care that aren’t seen until the patient reaches the 
pharmacy. Most of the tablet and capsule formulations are now available at a lower generic cost, 
but transdermal and oral suspension methylphenidate are still only available as the brand name 
agent. One way to expand the results of my research would be to incorporate some of this 
information along with the clinical information, therefore prescribers would be able to obtain all 
necessary information from one source.  
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Table 1. Available Extended-Release Methylphenidate Preparations 
Product Delivery Mechanism Time to 
peak 
(hours) 
Dosing 
Frequency 
Duration of 
action 
(hours) 
Available 
Doses 
Sprinkle/ 
Divide 
Ref. 
Ritalin® IR tablets 1-2 3 times daily 3-4 5, 10, 20mg Split/crush 15 
Ritalin SR® tablet, contains a wax 
based matrix 
4-5 2 times daily 8 20mg No, swallowed 
whole 
15 
Metadate 
ER® 
tablet, contains a wax 
based matrix 
4-5 2 times daily 8 10, 20mg No, swallowed 
whole 
16 
Methylin ER® tablet, dissolution 
polymer that extends 
MPH release 
3-4 2 times daily  8 10, 20mg No, swallowed 
whole 
17 
Concerta® tablet, osmotic pressure 
delivers racemic MPH 
mixture at a controlled 
rate 
1
st
: 1-2 
2
nd
: 6-8 
once daily 12 18, 27, 36, 
54, 72mg 
No, swallowed 
whole 
19 
Ritalin LA® capsule, contains 
mixture of MPH filled 
beads to allow 50% IR 
and 50% enteric coated 
delayed release 
1
st
: 1-3 
2
nd
: 4-5 
once daily 8-10 10, 20, 30, 
40mg 
Can be opened 
and sprinkled 
22 
Metadate 
CD® 
capsule, beaded drug 
delivery system with 
30% IR beads and 70% 
ER beads 
1
st
: 1.5 
2
nd
: 4.5 
once daily 8 10, 20, 30, 
40, 50, 
60mg 
Can be opened 
and sprinkled 
25 
Daytrana® transdermal patch 
releases MPH 
continuously 
10 once daily Dependent 
on wear 
time 
10, 15, 20, 
30mg 
Patch can’t be cut 
or damaged 
28 
Quillivant 
XR® 
suspension, 
reconstitute powder 
contains 20% IR 
component and 80% ER 
2-4 once daily 12 5mg/5mL 
-- 
33 
Focalin® IR tablets 
 
1-1.5 2 times daily 3-4 2.5, 5, 
10mg 
Split/crush 40 
Focalin XR® capsule, contains 
mixture of dex-MPH 
filled beads to allow 
50% IR and 50% enteric-
coated delayed-release 
1
st
: 1.5 
2
nd
: 6.5 
once daily 12 5, 10, 15, 
20, 25, 30, 
35, 40mg 
Can be opened 
and sprinkled 
40 
IR = immediate release, MPH = methylphenidate, ER = extended release  
 
